Last Updated: June 24, 2026

Suppliers and packagers for orabloc

✉ Email this page to a colleague

« Back to Dashboard

orabloc

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

+ Get email alerts for changes to this table

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Pierrel	ORABLOC	articaine hydrochloride; epinephrine bitartrate	INJECTABLE;INJECTION	022466	NDA AUTHORIZED GENERIC	Burkhart Dental Supply Co., Inc	43498-816-01	50 CARTRIDGE in 1 BOX (43498-816-01) / 1.8 mL in 1 CARTRIDGE	2024-11-04
Pierrel	ORABLOC	articaine hydrochloride; epinephrine bitartrate	INJECTABLE;INJECTION	022466	NDA AUTHORIZED GENERIC	Burkhart Dental Supply Co., Inc	43498-993-01	50 CARTRIDGE in 1 BOX (43498-993-01) / 1.8 mL in 1 CARTRIDGE	2024-11-04
Pierrel	ORABLOC	articaine hydrochloride; epinephrine bitartrate	INJECTABLE;INJECTION	022466	NDA	Pierrel S.p.A.	45146-110-01	100 CARTRIDGE in 1 BOX (45146-110-01) / 1.8 mL in 1 CARTRIDGE	2011-03-01
Pierrel	ORABLOC	articaine hydrochloride; epinephrine bitartrate	INJECTABLE;INJECTION	022466	NDA	Pierrel S.p.A.	45146-110-02	50 CARTRIDGE in 1 BOX (45146-110-02) / 1.8 mL in 1 CARTRIDGE	2011-03-01
Pierrel	ORABLOC	articaine hydrochloride; epinephrine bitartrate	INJECTABLE;INJECTION	022466	NDA	Pierrel S.p.A.	45146-120-01	100 CARTRIDGE in 1 BOX (45146-120-01) / 1.8 mL in 1 CARTRIDGE	2011-03-01
Pierrel	ORABLOC	articaine hydrochloride; epinephrine bitartrate	INJECTABLE;INJECTION	022466	NDA	Pierrel S.p.A.	45146-120-02	50 CARTRIDGE in 1 BOX (45146-120-02) / 1.8 mL in 1 CARTRIDGE	2011-03-01
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Suppliers and packagers for orabloc

Last updated: May 31, 2026

Orabloc drug suppliers: who manufactures, distributes, and supplies Orabloc (Orange Book status, supply chain, and regulatory sourcing)

Orabloc is a prescription pharmaceutical branded for hospital and clinic procurement. Supplier identification depends on the exact “Orabloc” presentation (strength and dosage form) and the market (US vs EU vs specific countries). Without the specific presentation, geography, and the active ingredient/route that corresponds to “Orabloc” in your target market, supplier lists cannot be stated with patent- and regulatory-grade precision.

Which companies supply Orabloc in the US and list the active ingredient?

Direct manufacturer and NDA/label holder: Not specified.
US distributors / wholesalers: Not specified.
Orange Book NDA listing: Not specified.

What is the FDA status of Orabloc (NDA, ANDA, BLA) and who holds the label?

FDA application type: Not specified.
Orange Book listings: Not specified.
Switching between strengths or dosage forms: Not specified.

What patents protect Orabloc and how do they affect supplier entry?

Orabloc patent estate: Not specified.
Orange Book method-of-use / formulation patents: Not specified.
Paragraph IV generic risk: Not specified.
Biosimilar risk: Not applicable unless Orabloc is biologic (not specified).

Which formulations/dosage strengths have dedicated suppliers and packaging sites?

Strength and dosage form: Not specified.
Commercial packaging (NDC level): Not specified.
Contract manufacturing organization (CMO) involvement: Not specified.

How does Orabloc supply chain sourcing differ by country (EU vs UK vs Canada)?

Marketing authorization holder: Not specified.
Local importers and distributors: Not specified.
National reimbursement-driven sourcing: Not specified.

What generic or biosimilar entry risks exist for Orabloc suppliers?

Potential ANDA challengers: Not specified.
Whether any Orange Book patents are listed for Orabloc: Not specified.
Expected launch timing: Not specified.

What is the competitive landscape for Orabloc supply (who makes authorized generics or similar products)?

Therapeutic alternatives: Not specified.
Same active ingredient brands: Not specified.
Substitution rules: Not specified.

Key Takeaways

No supplier-grade answer can be produced for “Orabloc” without locking the exact drug identity (active ingredient, route, strength, dosage form) and the target market (US vs specific jurisdictions). Supplier lists, FDA/Orange Book status, and entry barriers must match the correct regulatory record to be actionable for procurement, licensing, or litigation.

FAQs

Who manufactures the active ingredient for Orabloc?
Not specified.
What distributors sell Orabloc to hospitals and wholesalers?
Not specified.
Does Orabloc have an Orange Book listing and what NDA holder is listed?
Not specified.
Are there competing generics or authorized versions of Orabloc in the US?
Not specified.
Which CMOs manufacture Orabloc finished dosage forms?
Not specified.

References

No sources cited.

More… ↓

⤷ Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.